Cadrenal Therapeutics annual shares outstanding
2022
2023
2024
2025
Cadrenal Therapeutics Shares Outstanding History (CVKD)
Cadrenal Therapeutics reported 2.3M shares outstanding at the end of fiscal 2025.
View full Cadrenal Therapeutics company overviewCadrenal Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.3M | 555,641 | +31.17% |
| 2024 | 2024-12-31 | 1.8M | 914,302 | +105.31% |
| 2023 | 2023-12-31 | 868,184 | 321,925.667 | +58.93% |
| 2022 | 2022-12-31 | 546,258.333 | — | — |
Cadrenal Therapeutics quarterly shares outstanding
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
As of Aug 6, 2025
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.1M | 1.1M | +54.38% |
| Q1 2026 | 2026-03-31 | 2.5M | 597,085 | +31.27% |
| Q4 2025 | 2025-12-31 | 2.3M | 555,641 | +31.17% |
| Q3 2025 | 2025-09-30 | 2.1M | 825,082 | +66.83% |
| As of Aug 6, 2025 | 2025-08-06 | 2.0M | — | — |
| Q2 2025 | 2025-06-30 | 2.0M | 939,881.733 | +88.07% |
| Q1 2025 | 2025-03-31 | 1.9M | 842,500.733 | +78.94% |
| Q4 2024 | 2024-12-31 | 1.8M | 914,302 | +105.31% |
| Q3 2024 | 2024-09-30 | 1.2M | 366,488.4 | +42.21% |
| Q2 2024 | 2024-06-30 | 1.1M | 285,714.333 | +36.56% |
| Q1 2024 | 2024-03-31 | 1.1M | 285,714.333 | +36.56% |
| Q4 2023 | 2023-12-31 | 868,184 | 321,925.667 | +58.93% |
| Q3 2023 | 2023-09-30 | 868,183.6 | — | — |
| Q2 2023 | 2023-06-30 | 781,516.933 | — | — |
| Q1 2023 | 2023-03-31 | 781,516.933 | — | — |
| Q4 2022 | 2022-12-31 | 546,258.333 | — | — |
Cadrenal Therapeutics Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Cadrenal Therapeutics share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Cadrenal Therapeutics used $291,883 to repurchase common stock in fy 2025. Across the latest 2 reported fiscal years, total share repurchases were $291,883.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $291,883 |
| 2024 | 2024-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Cadrenal Therapeutics shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Cadrenal Therapeutics's shares outstanding moved from 546,258.333 to 2.3M, a change of 1.8M. The latest reported quarter, Q2 2026, shows 3.1M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cadrenal Therapeutics source filings ↗